BNTX
$89.27-0.04 (-0.04%)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 cl...
Recent News
European Equities Traded in the US as American Depositary Receipts Fall Sharply in Thursday Trading
European equities traded in the US as American depositary receipts were down sharply late Thursday m
European Equities Traded in US as ADRs Fall in Wednesday Trading
European equities traded in the US as American depositary receipts fell late Wednesday morning with
BioNTech Stock Is a Bargain. Why Its Recent Selloff Is a Buying Opportunity.
The company’s cash and securities nearly equal its market value, meaning investors aren’t paying much for the Covid franchise and a pipeline focused on cancer treatments.
Man's dog was riddled with tumors and dying. He used ChatGPT to design a custom cancer vaccine, stunning researchers
With no biology degree and just $3,000, he designed a personalized mRNA vaccine in a world first. Moderna and Merck are spending billions to bring the same technology to human patients.
Is BioNTech (BNTX) Starting To Look Attractive After Recent Share Price Weakness
If you are wondering whether BioNTech is starting to look like value after the Covid vaccine boom faded, or if the current price still feels rich, this article walks through what the numbers actually say about the stock. BioNTech shares last closed at US$90.84, after a 12.5% decline over 7 days, a 17.7% decline over 30 days, a 6.1% decline year to date, and a 9.4% decline over 1 year, with a 30.1% decline over 3 years and a 14.0% decline over 5 years. Recent coverage around BioNTech has...